Silver Book Fact

A recent study showed that memantine, a medicine approved to treat moderate-to-severe Alzheimer’s, significantly slows cognitive decline and reduces the need for caregiving by 45.8 hours per month.

Reisberg B, Doody R, Stoffler A, Schmitt F, et al. Memantine in Moderate-to-Severe Alzheimer’s Disease. New England Journal of Medicine. 2003; 348(14): 1333-41. http://content.nejm.org/cgi/content/abstract/348/14/1333?hits=20&where=fulltext&andorexactfulltext=and&searchterm=reisberg&sortspec=Score%2Bdesc%2BPUBDATE_SORTDATE%2Bdesc&excludeflag=TWEEK_element&searchid=1&FIRSTINDEX=0&resourcetype=HWCIT

Reference

Title
Memantine in Moderate-to-Severe Alzheimer’s Disease
Publication
New England Journal of Medicine
Publication Date
2003
Authors
Reisberg B, Doody R, Stoffler A, Schmitt F, et al
Volume & Issue
Volume 348, Issue 14
Pages
1333-41
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Human Value

Related Facts

  • Combining gains in health-related knowledge of Alzheimer’s disease and its application for both genders, reductions in mortality between 1970 and 2000 yielded additional life-years with an end of century value…  
  • Impact of Slowed Progression on Alzheimer’s Disease Growth, Americans Age 65 and Older with Alzheimer’s, 2010-2050  
  • “A treatment breakthrough that delayed the age of onset of Alzheimer’s disease by five years and began to show its effects in 2015 would decrease the total number of Americans…  
  • An Alzheimer’s treatment breakthrough that slowed disease progression and began to show effects in 2015, would reduce Medicaid costs for people with the disease by $62 billion–from the expected $178…  
  • According to the Pharmaceutical Research and Manufacturers of America, because of medical research, the number of Americans with Alzheimer’s could decrease by 3 million in 2025.